|
1.
|
|
|
2.
|
|
11 p, 1.2 MB |
Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients
/
García-López, Mireia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lens, Sabela (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Pallett, Laura J. (University College London) ;
Testoni, Barbara (University of Lyon) ;
Rodríguez-Tajes, Sergio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Mariño, Zoe (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Bartres, Concepció (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
García-Pras, Ester (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Leonel, Thais (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Perpiñán, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lozano, Juan José (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron) ;
Koutsoudakis, George (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Zoulim, Fabien (University of Lyon) ;
Maini, Mala K. (University College London) ;
Forns, Xavier (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Pérez-Del-Pulgar, Sofía (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Universitat Autònoma de Barcelona
Factors associated with a successful outcome upon nucleos(t)ide analogue (NA) treatment withdrawal in HBeAg-negative chronic hepatitis B (CHB) patients have yet to be clarified. The objective of this study was to analyse the HBV-specific T cell response, in parallel with peripheral and intrahepatic viral parameters, in patients undergoing NA discontinuation. [...]
2021 -  10.1016/j.jhep.2020.11.043
Journal of Hepatology, Vol. 74 (may 2021) , p. 1064-1074
|
|
|
3.
|
|
18 p, 4.0 MB |
Targeting OGG1 arrests cancer cell proliferation by inducing replication stress
/
Visnes, T. (Sintef Industry. Department of Biotechnology and Nanomedicine) ;
Benítez-Buelga, Carlos (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Cázares-Körner, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Sanjiv, K. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Hanna, Bishoy (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Mortusewicz, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rajagopal, Veera M (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Albers, J. J. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Hagey, D. W. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Bekkhus, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Eshtad, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Baquero, Juan Miguel (Centro Nacional de Investigaciones Oncológicas) ;
Masuyer, G. (University of Bath. Department of Pharmacy and Pharmacology) ;
Wallner, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Müller, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Pham, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Göktürk, C. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rasti, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Suman, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Torres, Raul (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sarno, A. (Sintef Ocean. Department of Environment and New Resources) ;
Wiita, E. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Homan, E. J. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Karsten, S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Marimuthu, K. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Michel, M. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Koolmeister, T. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Scobie, M. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Loseva, O. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Almlöf, I. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Unterlass, J. E. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Pettke, A. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Boström, J. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Pandey, M. (University of Sheffield. Weston Park Cancer Centre) ;
Gad, H. (University of Sheffield. Weston Park Cancer Centre) ;
Herr, P. (University of Sheffield. Weston Park Cancer Centre) ;
Jemth, A. S. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
El Andaloussi, S. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Kalderén, C. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Rodriguez-Perales, Sandra (Centro Nacional de Investigaciones Oncológicas) ;
Benítez, J. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Krokan, H. E. (Research and Innovation in Central Norway) ;
Altun, M. (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Stenmark, P. (Lund University. Department of Experimental Medical Science.) ;
Berglund, U. W. (Karolinska Institutet (Estocolm, Suècia). Department of Oncology and Pathology) ;
Helleday, Thomas (University of Sheffield.Weston Park Cancer Centre) ;
Universitat Autònoma de Barcelona
Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e. g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. [...]
2021 - 10.1093/nar/gkaa1048
Nucleic acids research, Vol. 48 Núm. 21 (february 2021) , p. 12234-12251
|
|
|
4.
|
|
16 p, 3.5 MB |
Conservation and variability of hepatitis B core at different chronic hepatitis stages
/
Yll, Marçal (Hospital Universitari Vall d'Hebron) ;
Cortese, Maria Francesca (Hospital Universitari Vall d'Hebron) ;
Guerrero Murillo, Mercedes (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Orriols, Gerard (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gregori i Font, Josep (Hospital Universitari Vall d'Hebron) ;
Casillas, Rosario (Hospital Universitari Vall d'Hebron) ;
González, Carolina (Hospital Universitari Vall d'Hebron) ;
Sopena, Sara (Hospital Universitari Vall d'Hebron) ;
Godoy, Cristina (Hospital Universitari Vall d'Hebron) ;
Vila, Marta (Hospital Universitari Vall d'Hebron) ;
Tabernero, David (Hospital Universitari Vall d'Hebron) ;
Quer, Josep 1963- (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rando-Segura, Ariadna (Hospital Universitari Vall d'Hebron) ;
Lopez Martinez, Rosa (Hospital Universitari Vall d'Hebron) ;
Esteban, Rafael (Esteban Mur) (Hospital Universitari Vall d'Hebron) ;
Riveiro Barciela, Mar (Hospital Universitari Vall d'Hebron) ;
Buti, Maria (Hospital Universitari Vall d'Hebron) ;
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Since it is currently not possible to eradicate hepatitis B virus (HBV) infection with existing treatments, research continues to uncover new therapeutic strategies. HBV core protein, encoded by the HBV core gene (HBC), intervenes in both structural and functional processes, and is a key protein in the HBV life cycle. [...]
2020 - 10.3748/wjg.v26.i20.2584
World Journal of Gastroenterology, Vol. 26 (may 2020) , p. 2584-2598
|
|
|
5.
|
|
13 p, 6.2 MB |
Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma
/
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Boloix, Ariadna (Institut de Ciència de Materials de Barcelona) ;
Masiá, Núria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
París-Coderch, Laia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Piskareva, Olga (Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital. Molecular and Cellular Therapeutics) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Henrich, Kai-Oliver (German Cancer Research Center (DKFZ). Neuroblastoma Genomics Group) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Westermann, Frank (German Cancer Research Center (DKFZ). Neuroblastoma Genomics Group) ;
Stallings, Raymond L. (Royal College of Surgeons in Ireland and National Children's Research Centre Our Lady's Children's Hospital. Molecular and Cellular Therapeutics) ;
Sábado, Constantino (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
de Toledo, Josep Sánchez (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Santamaría, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona ;
Hospital Universitari Vall d'Hebron
The online version of this article (10. 1007/s00018-019-03041-4) contains supplementary material, which is available to authorized users.
Current therapies for most non-infectious diseases are directed at or affect functionality of the human translated genome, barely 2% of all genetic information. By contrast, the therapeutic potential of targeting the transcriptome, ~ 70% of the genome, remains largely unexplored. [...]
2019 - 10.1007/s00018-019-03041-4
Cellular and Molecular Life Sciences, Vol. 76 (february 2019) , p. 2231-2243
|
|
|
6.
|
|
13 p, 1.6 MB |
Delivery is key: lessons learnt from developing splice-switching antisense therapies
/
Godfrey, Caroline (University of Oxford. Department of Physiology, Anatomy and Genetics) ;
Desviat, Lourdes R. (Centro de Biología Molecular Severo Ochoa) ;
Smedsrød, Bård (University of TromsØ. Department of Medical Biology) ;
Piétri-Rouxel, France (Institut de Myologie (París, França)) ;
Denti, Michela A. (Università di Trento. Centre for Integrative Biology) ;
Disterer, Petra (University College London. Centre for Amyloidosis and Acute Phase Proteins) ;
Lorain, Stéphanie (Institut de Myologie (París, França)) ;
Nogales, Gisela (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sardone, Valentina (University College London) ;
Anwar, Rayan (Drug Discovery Informatics Lap, Qasemi-Research Center, Al-Qasemi Academic College) ;
E. L. Andaloussi, Samir (Karolinska Institutet (Estocolm, Suècia). Department of Laboratory Medicine) ;
Lehto, Taavi (University of Tartu. Institute of Technology) ;
Khoo, Bernard (University College London. Centre for Neuroendocrinology) ;
Brolin, Camilla (University of Copenhagen. Department of Cellular and Molecular Medicine) ;
van Roon-Mom, Willeke M. C. (Leiden University Medical Center. DEpartment of Human Genetics) ;
Goyenvalle, Aurélie (Université Versailles Saint Quentin) ;
Aartsma-Rus, Annemieke (Leiden University Medical Center. Department of Human Genetics) ;
Arechavala-Gomeza, Virginia (Instituto de Investigación Sanitaria Biocruces Bizkaia) ;
Universitat Autònoma de Barcelona
The use of splice-switching antisense therapy is highly promising, with a wealth of pre-clinical data and numerous clinical trials ongoing. Nevertheless, its potential to treat a variety of disorders has yet to be realized. [...]
2017 - 10.15252/emmm.201607199
EMBO Molecular Medicine, Vol. 9 Núm. 5 (2017) , p. 545-557
|
|
|
7.
|
|
14 p, 1.3 MB |
Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy
/
González, Carolina (Hospital Universitari Vall d'Hebron) ;
Tabernero, David (Hospital Universitari Vall d'Hebron) ;
Cortese, Maria Francesca (Hospital Universitari Vall d'Hebron) ;
Gregori i Font, Josep (Roche Diagnostics SL) ;
Casillas, Rosario (Hospital Universitari Vall d'Hebron) ;
Riveiro Barciela, Mar (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Godoy, Cristina (Hospital Universitari Vall d'Hebron) ;
Sopena, Sara (Hospital Universitari Vall d'Hebron) ;
Rando-Segura, Ariadna (Hospital Universitari Vall d'Hebron) ;
Yll, Marçal (Hospital Universitari Vall d'Hebron) ;
Lopez Martinez, Rosa (Hospital Universitari Vall d'Hebron) ;
Quer, Josep 1963- (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Esteban, Rafael (Esteban Mur) (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Buti, Maria (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Rodríguez Frías, Francisco (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
To detect hyper-conserved regions in the hepatitis B virus (HBV) X gene (HBX) 5' region that could be candidates for gene therapy. The study included 27 chronic hepatitis B treatment-naive patients in various clinical stages (from chronic infection to cirrhosis and hepatocellular carcinoma, both HBeAg-negative and HBeAg-positive), and infected with HBV genotypes A-F and H. [...]
2018 - 10.3748/wjg.v24.i19.2095
World Journal of Gastroenterology, Vol. 24 (may 2018) , p. 2095-2107
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
